William G Christen1, Robert J Glynn1, J Michael Gaziano2, Amy K Darke3, John J Crowley3, Phyllis J Goodman3, Scott M Lippman4, Thomas E Lad5, James D Bearden6, Gary E Goodman7, Lori M Minasian8, Ian M Thompson9, Charles D Blanke10, Eric A Klein11. 1. Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. 2. Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts2Division of Aging, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts3Vet. 3. Southwest Oncology Group Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, Washington. 4. Office of the Director, Moores Cancer Center, University of California at San Diego. 5. Jesse Brown VA Medical Center, Chicago, Illinois. 6. Upstate Carolina Community Clinical Oncology Program/Spartanburg Regional Medical Center, Spartanburg, South Carolina. 7. Medical Oncology, Swedish Medical Center, Seattle, Washington. 8. Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland. 9. Department of Urology, Cancer Therapy and Research Center, University of Texas Health Science Center, San Antonio. 10. Southwest Oncology Group Chair's Office, Knight Cancer Institute, Oregon Health and Sciences University, Portland. 11. Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio.
Abstract
IMPORTANCE: Observational studies suggest a role for dietary nutrients such as vitamin E and selenium in cataract prevention. However, the results of randomized clinical trials of vitamin E supplements and cataract have been disappointing and are not yet available for selenium. OBJECTIVE: To test whether long-term supplementation with selenium and vitamin E affects the incidence of cataract in a large cohort of men. DESIGN, SETTING, AND PARTICIPANTS: The Selenium and Vitamin E Cancer Prevention Trial (SELECT) Eye Endpoints Study was an ancillary study of the Southwest Oncology Group-coordinated SELECT, a randomized placebo-controlled 4-arm trial of selenium and vitamin E conducted among 35,533 men, 50 years and older for African American participants and 55 years and older for all other men, at 427 participating sites in the United States, Canada, and Puerto Rico. A total of 11,267 SELECT participants from 128 SELECT sites participated in the SELECT Eye Endpoints ancillary study. INTERVENTIONS: Individual supplements of selenium (200 μg per day from L-selenomethionine) and vitamin E (400 IU per day of all rac-α-tocopheryl acetate). MAIN OUTCOMES AND MEASURES: Incident cataract was defined as a lens opacity, age related in origin, and responsible for a reduction in best-corrected visual acuity to 20/30 or worse based on self-reports confirmed by medical record review. Cataract extraction was defined as the surgical removal of an incident cataract. RESULTS: During a mean (SD) of 5.6 (1.2) years of treatment and follow-up, 389 cases of cataract were documented. There were 185 cataracts in the selenium group and 204 in the no selenium group (hazard ratio, 0.91; 95 % CI, 0.75-1.11; P = .37). For vitamin E, there were 197 cases in the treated group and 192 in the placebo group (hazard ratio, 1.02; 95 % CI, 0.84-1.25; P = .81). Similar results were observed for cataract extraction. CONCLUSIONS AND RELEVANCE: These data from a large cohort of apparently healthy men indicate that long-term daily supplementation with selenium and/or vitamin E is unlikely to have a large beneficial effect on age-related cataract. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT00784225.
RCT Entities:
IMPORTANCE: Observational studies suggest a role for dietary nutrients such as vitamin E and selenium in cataract prevention. However, the results of randomized clinical trials of vitamin E supplements and cataract have been disappointing and are not yet available for selenium. OBJECTIVE: To test whether long-term supplementation with selenium and vitamin E affects the incidence of cataract in a large cohort of men. DESIGN, SETTING, AND PARTICIPANTS: The Selenium and Vitamin ECancer Prevention Trial (SELECT) Eye Endpoints Study was an ancillary study of the Southwest Oncology Group-coordinated SELECT, a randomized placebo-controlled 4-arm trial of selenium and vitamin E conducted among 35,533 men, 50 years and older for African American participants and 55 years and older for all other men, at 427 participating sites in the United States, Canada, and Puerto Rico. A total of 11,267 SELECT participants from 128 SELECT sites participated in the SELECT Eye Endpoints ancillary study. INTERVENTIONS: Individual supplements of selenium (200 μg per day from L-selenomethionine) and vitamin E (400 IU per day of all rac-α-tocopheryl acetate). MAIN OUTCOMES AND MEASURES: Incident cataract was defined as a lens opacity, age related in origin, and responsible for a reduction in best-corrected visual acuity to 20/30 or worse based on self-reports confirmed by medical record review. Cataract extraction was defined as the surgical removal of an incident cataract. RESULTS: During a mean (SD) of 5.6 (1.2) years of treatment and follow-up, 389 cases of cataract were documented. There were 185 cataracts in the selenium group and 204 in the no selenium group (hazard ratio, 0.91; 95 % CI, 0.75-1.11; P = .37). For vitamin E, there were 197 cases in the treated group and 192 in the placebo group (hazard ratio, 1.02; 95 % CI, 0.84-1.25; P = .81). Similar results were observed for cataract extraction. CONCLUSIONS AND RELEVANCE: These data from a large cohort of apparently healthy men indicate that long-term daily supplementation with selenium and/or vitamin E is unlikely to have a large beneficial effect on age-related cataract. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT00784225.
Authors: Eric A Klein; Ian M Thompson; Catherine M Tangen; John J Crowley; M Scott Lucia; Phyllis J Goodman; Lori M Minasian; Leslie G Ford; Howard L Parnes; J Michael Gaziano; Daniel D Karp; Michael M Lieber; Philip J Walther; Laurence Klotz; J Kellogg Parsons; Joseph L Chin; Amy K Darke; Scott M Lippman; Gary E Goodman; Frank L Meyskens; Laurence H Baker Journal: JAMA Date: 2011-10-12 Impact factor: 56.272
Authors: William G Christen; Robert J Glynn; Howard D Sesso; Tobias Kurth; Jean MacFadyen; Vadim Bubes; Julie E Buring; JoAnn E Manson; J Michael Gaziano Journal: Arch Ophthalmol Date: 2010-11
Authors: O A Levander; G Alfthan; H Arvilommi; C G Gref; J K Huttunen; M Kataja; P Koivistoinen; J Pikkarainen Journal: Am J Clin Nutr Date: 1983-06 Impact factor: 7.045
Authors: William G Christen; Robert J Glynn; Joann E Manson; Jean MacFadyen; Vadim Bubes; Miriam Schvartz; Julie E Buring; Howard D Sesso; J Michael Gaziano Journal: Ophthalmology Date: 2013-11-20 Impact factor: 12.079
Authors: Scott M Lippman; Eric A Klein; Phyllis J Goodman; M Scott Lucia; Ian M Thompson; Leslie G Ford; Howard L Parnes; Lori M Minasian; J Michael Gaziano; Jo Ann Hartline; J Kellogg Parsons; James D Bearden; E David Crawford; Gary E Goodman; Jaime Claudio; Eric Winquist; Elise D Cook; Daniel D Karp; Philip Walther; Michael M Lieber; Alan R Kristal; Amy K Darke; Kathryn B Arnold; Patricia A Ganz; Regina M Santella; Demetrius Albanes; Philip R Taylor; Jeffrey L Probstfield; T J Jagpal; John J Crowley; Frank L Meyskens; Laurence H Baker; Charles A Coltman Journal: JAMA Date: 2008-12-09 Impact factor: 56.272
Authors: Alfredo García-Layana; Gianfranco Ciufo; Estefania Toledo; Miguel A Martínez-González; Dolores Corella; Montse Fitó; Ramon Estruch; Enrique Gómez-Gracia; Miguel Fiol; José Lapetra; Lluís Serra-Majem; Xavier Pintó; Maria P Portillo; José V Sorli; Mónica Bulló; Ernest Vinyoles; Aleix Sala-Vila; Emilio Ros; Jordi Salas-Salvadó; Fernando Arós Journal: Nutrients Date: 2017-05-03 Impact factor: 5.717
Authors: Zuzanna Micun; Martyna Falkowska; Maryla Młynarczyk; Jan Kochanowicz; Katarzyna Socha; Joanna Konopińska Journal: Int J Environ Res Public Health Date: 2022-08-20 Impact factor: 4.614
Authors: Phyllis J Goodman; Catherine M Tangen; Amy K Darke; Kathryn B Arnold; JoAnn Hartline; Monica Yee; Karen Anderson; Allison Caban-Holt; William G Christen; Patricia A Cassano; Peter Lance; Eric A Klein; John J Crowley; Lori M Minasian; Frank L Meyskens Journal: Trials Date: 2016-08-12 Impact factor: 2.279
Authors: Alex Langford-Smith; Viranga Tilakaratna; Paul R Lythgoe; Simon J Clark; Paul N Bishop; Anthony J Day Journal: PLoS One Date: 2016-01-21 Impact factor: 3.240